Pds biotech completes successful meeting with fda for triple combination of pds0101, pds0301 and a commercial immune checkpoint inhibitor

Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancer received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancer
PDSB Ratings Summary
PDSB Quant Ranking